Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.
about
A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships.The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat.A light in multidrug resistance: photodynamic treatment of multidrug-resistant tumors.Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells.Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line.Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoproteinEffect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoproteinOvercoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives.Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents.Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.Pharmacologic circumvention of multidrug resistance.Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.Interactions between P-glycoprotein and drugs used in the supportive care of acute myeloid leukemia patients.Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell lineSecondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies.In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative.SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia.Epidermal growth factor reduces resistance to doxorubicin.Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for cyclosporine.Synergistic effect of cyclosporin A and verapamil in overcoming vincristine resistance of multidrug-resistant cultured human leukemia cells.Human multi-drug-resistant cancer cells exhibit a high degree of selectivity for stereoisomers of verapamil and quinidine.Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin).In vivo model systems in P-glycoprotein-mediated multidrug resistance.Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporinsDevelopment of cyclosporin A mediated immunity in L1210 leukaemia.Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation.Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. A Gynecologic Oncology Group Study.Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia.Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay.The reversal of doxorubicin resistance by verapamil is not due to an effect on calcium channels.Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16.
P2860
Q33377470-C470D441-AD0F-4F46-B81F-47DB8B76C96BQ33418462-CC9B354F-BC8D-4F0A-B128-5DBFB3523B58Q33490842-855CAF8F-CC72-453E-90CB-F0EC35B70922Q35161693-ADB6A7A4-EC44-426E-87C9-3398355A505CQ35981946-F14CCD70-5DAF-4A3E-82F9-78CB1F89358BQ35982832-4540055F-32F7-406B-A523-7A4805D716E1Q36080906-B7CD3584-F077-4469-9981-86491D6F46C7Q36115251-83D45B3A-6852-4480-BF00-E94EC1A2AD34Q36466963-BE6CECE2-E1C5-4B4A-82F5-A05CE376770FQ36467823-90474D4C-EB40-428D-B1FD-2B93988A084CQ40304647-178F0E3F-F56E-402D-A09A-3C3C7E6472F0Q40340521-AD9E403E-F760-4700-A4D8-B2AFA99A977DQ40535280-3F66A4F3-116A-4A35-8204-B8069E2F1E83Q40618716-41365288-976D-4E49-9343-67F77C0E3C9BQ40769755-65D09AC9-5DC6-4FEF-B98C-C4EA501C141DQ41147831-5E820A00-5C12-407C-864E-A24434EE580AQ41503151-3E552D0A-25E8-4816-8602-9E4345B4FD5EQ41525074-95BC1AB6-4293-444F-B6B2-D6511BDFCD2EQ41610629-83D87E16-704A-455A-8F24-EEF8E5F3440AQ41639342-4A0B9D04-714C-436B-B1B2-377E5CC20CABQ41669174-D05A9522-22BF-43BF-852C-49B6B8F035B8Q41707631-566E4B33-7D3E-431F-ADE2-32C5BF5FE239Q41727067-A55D6572-0F79-494A-A378-285DE4A9447FQ41727991-5B32A91A-9C9E-4E2E-9248-DA731204FB92Q41729794-FBB38AB7-8F5B-4297-A3A7-B96ED503AF94Q41734226-E815E2E3-A4FA-4C2D-A9F4-659374311F52Q41812714-D1AEE060-815A-4311-A9B9-20A7612D9AF9Q42371807-BD796B11-ADAC-488C-89F5-DE3594EE5389Q43631965-22281FC8-3F55-4B2F-9B02-6910EAE09D90Q43777030-C9EC23A1-37C8-4ACA-972B-D0A88594F7DCQ44204487-B473971A-6055-40B2-BAA2-D1F052F1C391Q46050963-E252BD09-5619-4014-A22B-AD49A6E75F56Q50892060-996595EB-D66B-4D04-B662-DBB1D97731C0Q54186927-C107746E-FDD3-4BD8-9CEA-8773B69A4830Q54231423-1D5242AE-9073-4925-921C-A3B498F8B37CQ54267590-A767C117-05E7-4EBA-8ED6-D66A59C2D408Q54362264-B04485DE-19D6-479C-9536-C9EF0DE12BC7Q54388638-F964B733-1772-45F1-B508-76AD8DE7639DQ55019227-4D45CF5B-05B4-4531-BC91-FA8C3BF46259
P2860
Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.
@en
type
label
Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.
@en
prefLabel
Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.
@en
P2093
P2860
P356
P1476
Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1986.167
P407
P577
1986-08-01T00:00:00Z